Defac 6mg Tablet (Deflazacort)

Description

Defac 6mg Tablet (Deflazacort) — Complete Clinical and Patient Information Guide

Product Overview

Defac 6mg Tablet (Deflazacort) contains Deflazacort 6mg as its active pharmaceutical ingredient, belonging to the synthetic oxazoline glucocorticoid — bone-sparing corticosteroid. It is clinically indicated for inflammatory and autoimmune conditions requiring systemic corticosteroid therapy — including juvenile idiopathic arthritis, nephrotic syndrome, systemic lupus erythematosus, inflammatory myopathies, Duchenne muscular dystrophy (FDA-approved indication at higher doses), severe asthma, and autoimmune conditions where bone-sparing is clinically important. This guide is prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. Cancer and specialty medications require specialist initiation and monitoring — this information is educational and does not replace professional medical guidance.

Defac 6mg provides deflazacort 6mg — the bone-sparing corticosteroid preferred for long-term inflammatory disease management.

Mechanism of Action

Deflazacort is a synthetic oxazoline corticosteroid derived from prednisolone, with approximately 0.78 times the anti-inflammatory potency of prednisolone on an equal milligram basis (6mg deflazacort ≈ 5mg prednisolone). Deflazacort is a prodrug that is rapidly converted in the body to its active metabolite 21-hydroxy-deflazacort. Its glucocorticoid receptor-mediated mechanism follows the same GR-transcriptional regulation pathway as other systemic corticosteroids: GR binding, nuclear translocation, and modulation of gene transcription to suppress pro-inflammatory cytokines (IL-1, IL-2, IL-6, TNF-alpha), reduce adhesion molecule expression, and inhibit phospholipase A2. However, deflazacort’s key clinical advantage over prednisolone is its significantly reduced effect on calcium/phosphorus metabolism, resulting in markedly less bone loss and osteoporosis compared to prednisolone at equivalent anti-inflammatory doses — making it preferred for patients who require long-term systemic corticosteroid therapy, particularly children (where bone growth and density are critical).

Clinical Indications

Defac 6mg Tablet (Deflazacort) is indicated for inflammatory and autoimmune conditions requiring systemic corticosteroid therapy — including juvenile idiopathic arthritis, nephrotic syndrome, systemic lupus erythematosus, inflammatory myopathies, Duchenne muscular dystrophy (FDA-approved indication at higher doses), severe asthma, and autoimmune conditions where bone-sparing is clinically important. Specialist confirmation of diagnosis, eligibility for treatment, and initiation of therapy are mandatory — self-diagnosis and self-treatment of these conditions can be dangerous and may delay or undermine appropriate clinical management.

Dosage and Administration

Dosing is individualised: anti-inflammatory maintenance doses typically 6–18mg/day; acute treatment/higher doses as prescribed. Deflazacort 6mg ≈ prednisolone 5mg in anti-inflammatory equivalence. Take with food to reduce GI irritation.

Contraindications

Active untreated systemic infections. Hypersensitivity to deflazacort or any excipient. Live virus vaccination during significant immunosuppression.

Drug Interactions

NSAIDs: additive GI toxicity. Warfarin: altered anticoagulant effect — monitor INR. Antidiabetics: corticosteroid-induced hyperglycaemia requiring dose adjustment. CYP3A4 inhibitors (ketoconazole, ritonavir): increase deflazacort levels. Rifampicin/phenytoin: reduce efficacy. Live vaccines: contraindicated during significant immunosuppression.

Adverse Effects

Short-term: hyperglycaemia, fluid retention, mood changes, insomnia, increased appetite. Long-term: adrenal suppression (taper gradually after prolonged courses), osteoporosis (significantly less than prednisolone — key advantage), Cushingoid features, susceptibility to infections. Deflazacort’s reduced bone loss risk is its principal clinical advantage over prednisolone.

Special Population Considerations

BONE PROTECTION ADVANTAGE: Deflazacort’s principal clinical advantage over prednisolone and other corticosteroids is significantly reduced calcium metabolism disruption — producing approximately 50% less bone loss compared to prednisolone at equivalent anti-inflammatory doses. This makes deflazacort particularly preferred for: children requiring prolonged corticosteroid therapy (bone growth preservation); post-menopausal women at osteoporosis risk; and patients with Duchenne muscular dystrophy requiring long-term high-dose therapy. ADRENAL SUPPRESSION: Never stop deflazacort abruptly after prolonged courses — gradual dose tapering is mandatory under medical supervision. STEROID CARD: Patients on regular systemic deflazacort should carry a steroid alert card.

Storage

Store Defac 6mg per manufacturer guidelines. Most oral tablets at room temperature (15–25°C) away from heat, light, and moisture. Injectable medications require refrigeration or specific temperature control — follow pharmacy instructions. Keep out of reach of children and dispose of expired medications through authorised pharmaceutical take-back services.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Injectable oncology medications require specialised storage — follow manufacturer and pharmacy guidance. Do not use beyond the printed expiry date.

Q: What should I do if I miss a dose?
A: For most medications: take as soon as you remember unless it is nearly time for the next dose. Never double-dose. For oncology medications, missed doses should be discussed with your oncologist before taking. Do not stop cancer medications without oncologist guidance.

Q: Why is deflazacort preferred over prednisolone for long-term use?
A: Deflazacort has approximately 50% less effect on bone mineral density compared to prednisolone at equivalent anti-inflammatory doses. This reduced osteoporotic risk is particularly important for children (where bone growth is critical), elderly patients with existing osteoporosis risk, and patients requiring prolonged courses. In Duchenne muscular dystrophy, where long-term high-dose corticosteroid therapy is standard of care, deflazacort’s FDA approval is based specifically on efficacy data alongside this improved bone safety profile.

Evidence Base, Regulatory Status, and Quality Standards

The active ingredient in Defac 6mg has been evaluated in clinical trials and regulatory submissions reviewed by competent health authorities. Oncology and specialty medications are subject to stringent regulatory scrutiny given their risk-benefit profiles in serious conditions. Major oncology guidelines from ESMO, ASCO, NCCN, and relevant national bodies inform prescribing decisions. All medications should be obtained through licensed, regulated pharmacies with valid prescriptions from registered specialists to ensure receipt of authentic, quality-assured products. GMP compliance ensures consistent product quality, identity, strength, and purity.

Corticosteroid Therapy Clinical Context

Systemic corticosteroid therapy is among the most widely used pharmacological interventions globally — providing powerful anti-inflammatory and immunosuppressive effects essential for managing a vast range of conditions. The challenge of systemic corticosteroid therapy is balancing therapeutic benefit against the well-documented adverse effects of prolonged exposure: osteoporosis, adrenal suppression, metabolic dysregulation (diabetes, dyslipidaemia), cardiovascular risk, and immunosuppression. Deflazacort’s bone-sparing profile addresses one of the most prevalent and disabling long-term corticosteroid complications.

Duchenne muscular dystrophy (DMD) represents one of deflazacort’s most important therapeutic niches — it is the only FDA-approved corticosteroid for DMD, with evidence showing superior functional preservation compared to prednisolone while producing less weight gain and better bone protection over the extended treatment periods required (years to decades). The CINRG trial established deflazacort’s advantages in DMD longitudinal function preservation.

Evidence Base and Quality Standards

Deflazacort’s clinical profile — anti-inflammatory equivalence to prednisolone with significantly reduced bone and metabolic adverse effects — is supported by multiple comparative studies. All corticosteroid therapy requires regular monitoring: blood pressure, blood glucose, bone density (DEXA), adrenal function assessment for prolonged therapy, and ophthalmological review (cataracts, glaucoma). GMP compliance ensures consistent product quality. Patients should obtain prescription corticosteroids from licensed pharmacies with valid specialist prescriptions.

Patient Safety, Monitoring, and Adherence

Oncology and specialty pharmacotherapy requires active patient engagement for optimal outcomes. Adherence to oral cancer drugs is critical — missed doses of TKIs like imatinib, erlotinib, and enzalutamide directly reduce drug exposure and potentially allow tumour progression or drug resistance development. Studies in CML show that patients with <80% imatinib adherence have significantly worse molecular response rates and higher transformation risk. The same principle applies to endocrine therapy for breast cancer — patients discontinuing anastrozole or tamoxifen early have substantially higher recurrence rates. Adherence support, side effect management, and patient education are as important as drug selection.

Monitoring requirements for specialty medications are stringent and non-negotiable. FBC monitoring during chemotherapy and methotrexate therapy prevents life-threatening myelosuppression complications. LFT monitoring during TKI and anthracycline therapy detects hepatotoxicity before it becomes severe. Cardiac monitoring during trastuzumab and anthracycline therapy prevents irreversible cardiomyopathy. Molecular monitoring (BCR-ABL PCR, HCV RNA, HBV DNA) determines treatment response and guides duration decisions.

All patients on oncology and specialty medications benefit from structured support: specialist oncology nurse coordination, patient support groups, pharmacist medication counselling, and regular specialist review. Complex medication regimens should be clearly written, explained verbally, and reviewed at each clinical encounter to identify any confusion, interactions, or emerging side effects requiring management.

Responsible Use and Safe Disposal

Oncology medications — particularly oral cytotoxic agents (cyclophosphamide, capecitabine, temozolomide, methotrexate) — are hazardous drugs requiring careful handling. Pregnant women and those planning pregnancy should not handle broken or crushed oral cytotoxic tablets. Unused or expired medications must be returned to a licensed pharmacy for safe hazardous pharmaceutical disposal — never disposed of in household waste or toilet.

Multi-Disciplinary Oncology Care

Modern cancer management requires multi-disciplinary team (MDT) decision-making — integrating oncologists, surgeons, radiologists, pathologists, specialist nurses, and pharmacists to develop individualised treatment plans. Pharmacological therapy (chemotherapy, targeted agents, endocrine therapy, immunotherapy) is one component of comprehensive cancer care alongside surgery (with curative intent for localised disease), radiotherapy (definitive, adjuvant, or palliative), and supportive/palliative care. Clinical trials offer access to novel therapies and the opportunity to advance cancer treatment knowledge — eligible patients should be offered trial participation where available.

Oncology pharmacy practice has become a specialised discipline — oncology pharmacists review complex multi-drug regimens for interactions and dosing errors, prepare hazardous IV chemotherapy safely, counsel patients on managing side effects of oral cancer drugs, and monitor for drug-induced toxicities. The safe use of oncology medications depends on this specialised expertise at every step from prescription to administration.

Palliative and supportive care integration is equally important — managing cancer symptoms (pain, nausea, fatigue, dyspnoea) and treatment side effects (chemotherapy-induced nausea, peripheral neuropathy, immunosuppression, mucositis) maintains quality of life throughout the cancer journey. Early palliative care integration (not just end-of-life care) improves patient outcomes and quality of life even in patients receiving active curative therapy.

Drug Supply and Authentic Procurement

For oncology and specialty medicines, procurement from authenticated, licensed sources is critically important. Counterfeit cancer medications are a documented global public health problem — they range from diluted products (containing less active ingredient than labelled, providing inadequate treatment) to products containing no active ingredient, to products with contaminated or substituted ingredients causing direct harm. Always obtain cancer medications from licensed, regulated pharmacies with valid prescriptions. Indian regulatory authority (CDSCO) oversight and manufacturer GMP compliance provide assurance of product quality for domestically produced cancer medicines.

Managing Treatment Toxicities

Cancer treatments — chemotherapy, targeted agents, immunotherapy, and endocrine therapy — all carry toxicity profiles requiring proactive management. Common toxicity management principles include: dose modification grids (reduce dose for Grade 2+ toxicities; suspend for Grade 3; permanently discontinue for Grade 4 in most instances) standardised across CTCAE (Common Terminology Criteria for Adverse Events); prophylactic antiemetics before highly emetogenic chemotherapy (5-HT3 antagonists, NK1 inhibitors, dexamethasone — the triad for highly emetogenic regimens); G-CSF prophylaxis for regimens with >20% febrile neutropaenia risk; mucositis management (good oral hygiene, topical anaesthetics, sucralfate); and peripheral neuropathy monitoring with dose modification protocols.

Patient-reported outcomes — symptoms experienced and reported by patients directly — are increasingly recognised as essential quality-of-care metrics. Patient-reported nausea, fatigue, neuropathy, and quality of life scores complement objective clinical and laboratory monitoring in capturing the full clinical picture and guiding treatment modification decisions. Oncology patients should be encouraged to actively report symptoms to their care team — prompt reporting allows early intervention before toxicities escalate to treatment-limiting severity.

Infertility is an important long-term consequence of many chemotherapy regimens and hormonal therapies — particularly alkylating agents (cyclophosphamide) and GnRH agonists (leuprolide). Fertility preservation consultation (sperm banking, oocyte/embryo cryopreservation) should be offered to all cancer patients of reproductive age before starting gonadotoxic therapy — ideally before treatment begins, as the window for preservation is limited.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological and oncological literature, and established clinical guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified oncologist, haematologist, physician, or specialist pharmacist. Cancer drug therapy decisions require individualised assessment by qualified oncology professionals with full knowledge of the patient’s diagnosis, staging, molecular profile, performance status, and concurrent medications. Self-diagnosis and self-treatment of cancer and serious medical conditions can be life-threatening. Always consult a qualified specialist before starting, changing, or stopping any cancer or specialty medication.